A framework for decision making of migraine treatment with anti- CGRP monoclonal antibodies: a guide for real-world practice and public policies

Authors

DOI:

https://doi.org/10.48208/HeadacheMed.2020.20

Keywords:

Migraine Disorders, Calcitonin Gene-Related Peptide, Algorithms, Antibodies, Monoclonal, Public Health

Abstract

Anti-CGRP monoclonal antibodies have been developed for migraine preventive treatment. There is evidence of good efficacy and safety of these medications; however, cost is a factor that interferes with the choice of treatment. This paper proposes a framework in order to better assist the decision-making processes on the use of these drugs in developing countries without coverage of health care costs for migraine. The framework was built after reviewing phase II and III studies on episodic and chronic migraine treatment with erenumab, galcanezumab and fremanezumab.

Downloads

Download data is not yet available.

Author Biographies

Reinilza Nunes da Gama, Hospital Israelita Albert Einstein

Hospital Israelita Albert Einstein, Neurology, São Paulo, São Paulo, Brazil

Thaiza Agostini Córdoba de Lima, Hospital Israelita Albert Einstein

Hospital Israelita Albert Einstein, Neurology, São Paulo, São Paulo, Brazil

Iron Dangoni Filho, Hospital Israelita Albert Einstein

Hospital Israelita Albert Einstein, Neurology, São Paulo, São Paulo, Brazil

Mario Fernando Prieto Peres, Hospital Israelita Albert Einstein

Hospital Israelita Albert Einstein, Neurology, São Paulo, São Paulo, Brazil

Downloads

Published

30/09/2020

How to Cite

1.
Gama RN da, Lima TAC de, Dangoni Filho I, Peres MFP. A framework for decision making of migraine treatment with anti- CGRP monoclonal antibodies: a guide for real-world practice and public policies. HM [Internet]. 2020 Sep. 30 [cited 2021 Sep. 26];11(3):72-6. Available from: https://headachemedicine.com.br/index.php/hm/article/view/414

Issue

Section

Original

Most read articles by the same author(s)

1 2 > >>